Mark Day Biography and Net Worth

Mark J. Day serves as iRhythm’s Chief Technology Officer and was formerly the Executive Vice President of Research & Development. He has had other leadership roles in Research & Development and systems development since joining in 2007. Previously he worked in Medtronic’s Cardiac Rhythm Disease Management division. Prior to that, Mr. Day was Chief Technical Officer of CarePages, Inc., a blogging site for patients. Mr. Day has an M.B.A. in Marketing from the Wharton School, University of Pennsylvania, a Ph.D. in Computation Flow Physics from Stanford University, and also received an M.S. from Stanford, and a B.Sc. from Queen’s University, both in Mechanical Engineering.

What is Mark J. Day's net worth?: The estimated net worth of Mark J. Day is at least $4.75 million as of February 29th, 2024. Mr. Day owns 64,412 shares of iRhythm Technologies stock worth more than $4,749,741 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Day may own. Learn More about Mark J. Day's net worth.
How do I contact Mark J. Day?: The corporate mailing address for Mr. Day and other iRhythm Technologies executives is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. iRhythm Technologies can also be reached via phone at (415) 632-5700 and via email at [email protected]. Learn More on Mark J. Day's contact information.
Has Mark J. Day been buying or selling shares of iRhythm Technologies?: Mark J. Day has not been actively trading shares of iRhythm Technologies in the last ninety days. Most recently, Mark J. Day sold 1,475 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $121.96, for a transaction totalling $179,891.00. Following the completion of the sale, the chief technology officer now directly owns 64,412 shares of the company's stock, valued at $7,855,687.52. Learn More on Mark J. Day's trading history.
Who are iRhythm Technologies' active insiders?: iRhythm Technologies' insider roster includes C. Bairey Merz (Director), Quentin Blackford (CEO), Mark Day (EVP), Douglas Devine (CFO), Patrick Murphy (EVP), Chad Patterson (Chief Commercial Officer), Sumi Shrishrimal (EVP, Chief Risk Officer), Mervin Smith (EVP of Business Operations), Minang Turakhia (Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation), David Vort (EVP), and Daniel Wilson (EVP). Learn More on iRhythm Technologies' active insiders.
Are insiders buying or selling shares of iRhythm Technologies?: In the last year, iRhythm Technologies insiders bought shares 2 times. They purchased a total of 6,944 shares worth more than $521,860.64. In the last year, insiders at the sold shares 12 times. They sold a total of 66,532 shares worth more than $6,937,400.34. The most recent insider tranaction occured on November, 4th when Director Abhijit Y Talwalkar bought 6,664 shares worth more than $500,866.24. Insiders at iRhythm Technologies own 0.7% of the company. Learn More about insider trades at iRhythm Technologies.
Information on this page was last updated on 11/4/2024.

Mark J. Day Insider Trading History at iRhythm Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/29/2024	Sell	1,475	$121.96	$179,891.00	64,412
3/3/2023	Sell	2,116	$117.23	$248,058.68	54,815
2/28/2023	Sell	1,913	$117.84	$225,427.92	56,931
10/1/2020	Sell	17,500	$230.17	$4,027,975.00	37,369

Mark J. Day Buying and Selling Activity at iRhythm Technologies

iRhythm Technologies Company Overview

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $73.74

$72.36

$75.15

50 Day Range

MA: $72.82

$57.07

$89.50

2 Week Range

Now: $73.74

$55.92

$124.11

Volume

558,042 shs

Average Volume

613,413 shs

Market Capitalization

$2.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late